Table 5 Univariate prognostic factor analysis
From: The role of radiotherapy in the management of POEMS syndrome
Factor | No. of case | 3-year PFS (%) | p value * | 3-year OS (%) | p value * |
|---|---|---|---|---|---|
Age >50 years (vs. ≤50 years) | 13/20 | 53.3/62.4 | 0.931 | 56.4/66.0 | 0.259 |
Radiotherapy (Y/N) | 13/20 | 64.8/56.7 | 0.310 | 66.6/59.4 | 0.782 |
Chemotherapy (Y/N) | 25/8 | 71.5/17.5 | 0.007 | 74.1/18.2 | 0.020 |
HD Chemotherapy with ABSCT (vs. SD chemotherapy) | 15/10 | 80.8/58.3 | 0.291 | 78.8/66.7 | 0.253 |
IgG M-protein subtype (vs. other subtypes) | 17/16 | 54.4/65.6 | 0.719 | 61.1/65.8 | 0.775 |
VEGF elevation without gross lesion (vs. other subtypes) | 6/27 | 25.0/66.0 | 0.035 | 16.7/74.1 | 0.008 |
BM plasma cells more than 5% (vs. ≤5%) | 13/20 | 61.4/59.5 | 0.771 | 60.6/62.5 | 0.821 |
The presence of abnormal clonal plasma cells in BM (Y/N) | 5/28 | 60.0/60.8 | 0.249 | 80.0/60.4 | 0.552 |
Extravascular volume overload except peripheral edema (Y/N) | 16/17 | 49.2/70.0 | 0.155 | 53.5/71.1 | 0.212 |
Number of POEMS features >7 (vs. ≤7) | 14/19 | 46.4/67.7 | 0.220 | 45.9/74.2 | 0.127 |
Multiple bone lesions (vs. single bone lesion) | 12/11 | 62.3/66.3 | 0.742 | 77.9/70.7 | 0.906 |